Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live09-22 20:50

Vertex Pharmaceuticals (VRTX) said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.

The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.

The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.

Shares of Vertex were up 2.2% pre-bell.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2669425861?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669425861","market":"sh","top_or_hot":-1,"title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","media":"MT Newswires Live","content":"<html><body><p> Vertex Pharmaceuticals (VRTX) said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.</p><p>The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.</p><p>The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.</p><p>Shares of Vertex were up 2.2% pre-bell.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-22 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Vertex Pharmaceuticals (VRTX) said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.</p><p>The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.</p><p>The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.</p><p>Shares of Vertex were up 2.2% pre-bell.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ9MQY76.HKD","symbol_name":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2669425861","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","pubTimestamp":1790081406,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","VERX":"Vertex, Inc.","BK4023":"应用软件","BK4532":"文艺复兴科技持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","BK4567":"ESG概念","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","BIB":"Ultra纳斯达克生物科","BK4139":"生物科技","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IBBQ":"Invesco Nasdaq Biotechnology ETF","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0079474960.USD":"联博美国增长基金A","VRTX":"福泰制药","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","GNMX":"Corgi Genomics & Precision Medicine ETF","TBXU":"Direxion Daily Biotech Top 5 Bull 2X ETF","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","IDNA":"iShares Genomics Immunology and Healthcare ETF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4588":"碎股","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BBH":"VanEck Biotech ETF","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0566484027.USD":"安本美国小盘成长股","SG9999001176.USD":"United Global Healthcare Acc USD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC"},"translate_title":"Vertex Pharmaceuticals 报告 Inaxaplin 肾脏疾病试验取得积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDNA":0.6,"IBB":0.6,"VRTX":1.5,"IBBQ":0.6,"TBXU":0.6,"BBH":0.6,"PBE":0.6,"VERX":1.5,"GNMX":0.6,"BIB":0.6},"content_text":"Vertex Pharmaceuticals (VRTX) said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669425861","isCrawlerRequest":true}